Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

B-Cell Hodgkin Lymphoma Pipeline market research report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

Key Targets in the B-Cell Hodgkin Lymphoma Pipeline Market

The key targets in the B-Cell Hodgkin Lymphoma Pipeline market are Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2, and Cells Expressing B Lymphocyte Antigen CD19. Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 has the highest number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by Targets

B-Cell Hodgkin Lymphoma Pipeline Market, by Targets

For more target insights, download a free report sample

Types of MoA in the B-Cell Hodgkin Lymphoma Pipeline Market

The key mechanisms of action in the B-Cell Hodgkin Lymphoma Pipeline market are Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor. Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 has the maximum number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by MoA

B-Cell Hodgkin Lymphoma Pipeline Market, by MoA

For more MoA insights, download a free report sample

Types of RoA in the B-Cell Hodgkin Lymphoma Pipeline Market

The types of key RoA in the B-Cell Hodgkin Lymphoma Pipeline market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, intralesional, intraperitoneal, and topical. In the B-Cell Hodgkin Lymphoma Pipeline market, intravenous has the highest number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by RoA

B-Cell Hodgkin Lymphoma Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the B-Cell Hodgkin Lymphoma Pipeline Market

The key molecule types in the B-Cell Hodgkin Lymphoma Pipeline market are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, cell therapy, fusion protein, antibody, antisense RNAi oligonucleotide, gene therapy, and oligonucleotide. Small molecule has the highest number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by Molecule Type

B-Cell Hodgkin Lymphoma Pipeline Market, by Molecule Type

For more molecule type insights, download a free report sample

Key Companies in the B-Cell Hodgkin Lymphoma Pipeline Market

The key companies in the B-Cell Hodgkin Lymphoma Pipeline market are Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc. Bristol-Myers Squibb Co has the majority number of pipeline products.

B-Cell Hodgkin Lymphoma Pipeline Market, by Companies

B-Cell Hodgkin Lymphoma Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2, and Cells Expressing B Lymphocyte Antigen CD19
Key MoA Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor
Key RoA Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Intralesional, Intraperitoneal, and Topical
Key molecule types Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Antibody, Antisense RNAi Oligonucleotide, Gene Therapy, and Oligonucleotide
Key companies Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Affimed GmbH
Alfasigma SpA
Angiocrine Bioscience Inc
Apollomics Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Avipep Pty Ltd
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
Biohaven Pharmaceutical Holding Company Ltd
Bristol-Myers Squibb Co
Carrick Therapeutics Ltd
Catalent Inc
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellular Biomedicine Group Inc
Celularity Inc
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chimeric Therapeutics Ltd
CSL Ltd
CStone Pharmaceuticals Co Ltd
Curis Inc
Daiichi Sankyo Co Ltd
Dyadic International Inc
Eutilex Co Ltd
Faron Pharmaceuticals Oy
Genentech USA Inc
Gibson Oncology LLC
Gilead Sciences Inc
Glenmark Pharmaceuticals Ltd
Guangzhou Sinogen Pharmaceutical Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Helocyte Biosciences Inc
HRAIN Biotechnology Co Ltd
Hutchison MediPharma Ltd
Immune Cell Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Incyte Corp
Inhibrx Inc
Innovent Biologics Inc
Intellia Therapeutics Inc
Kymera Therapeutics Inc
LegoChem Biosciences Inc
Luye Pharma Group Ltd
Magenta Therapeutics Inc
Marker Therapeutics Inc
MediSix Therapeutics Pte Ltd
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec BV & Co KG
Mirati Therapeutics Inc
NewBio Therapeutics Inc
Northlake International LLC
OncoTartis Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
PlantForm Corp
Protheragen Inc
Rafael Pharmaceuticals Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Rich Pharmaceuticals Inc
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
Seagen Inc
Shanghai First Song Therapeutics Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SpecificiT Pharma Inc
Suzhou Everhealth Biomedical Co Ltd
Syndax Pharmaceuticals Inc
Tacitus Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tessa Therapeutics Ltd
Tevogen Bio Inc
Tubulis GmbH
Tyme Inc
Vincerx Pharma Inc
Viracta Therapeutics Inc
Waterstone Hanxbio Pty Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Xencor Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Companies Involved in Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drug Profiles

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Product Development Milestones

Featured News & Press Releases

Apr 11, 2022: Glenmark Specialty S.A. receives approval for conducting phase 1 clinical trial of its novel molecule GRC 54276 in patients with advanced solid tumors and Hodgkin’s lymphoma

Apr 10, 2022: Affimed presents updated clinical data from phase 1/2 study of AFM13 precomplexed with cord blood-derived NK cells at AACR Annual Meeting

Dec 14, 2021: Tessa Therapeutics announces positive data from phase 2 trial of autologous CD30-CAR-T therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting

Dec 12, 2021: Seagen announces preliminary results from phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in novel combination of agents for patients with advanced stage classical hodgkin lymphoma

Dec 09, 2021: Affimed to host virtual investor call today to discuss treatment of CD30-positive lymphoma patients with cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13

Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in three new indications

Dec 02, 2021: Innovent and Lilly announce successful expansion of Sintilimab in China National Reimbursement Drug List to include three additional first-line indications

Nov 04, 2021: Seagen to highlight multiple ADCETRIS (brentuximab vedotin) data presentations at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting

Nov 03, 2021: Tessa Therapeutics announces presentation of autologous cell therapy data at 2021 ASH Annual Meeting

Sep 27, 2021: ONO receives approval of Opdivo (nivolumab) for dosage and administration for treatment of Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma in Japan

Aug 30, 2021: Ligand’s partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin’s lymphoma

Jun 22, 2021: ADC Therapeutics announces encouraging interim results from pivotal phase 2 clinical trial of Camidanlumab Tesirine (Cami) presented at the 16th Annual International Conference on Malignant Lymphoma

Jun 09, 2021: ADC Therapeutics announces presentation on Camidanlumab at the 16th Annual International Conference on Malignant Lymphoma

May 26, 2021: ADC Therapeutics announces online publication of Camidanlumab Tesirine phase 1 results in The Lancet Haematology

May 14, 2021: Tessa Therapeutics announces positive, topline data from ongoing phase 1 trial of allogeneic, “Off-the-Shelf” cell therapy, in patients with relapsed or refractory CD30-positive lymphoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Adlai Nortye Biopharma Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alfasigma SpA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Angiocrine Bioscience Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Apollomics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Astellas Pharma Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AstraZeneca Plc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aurigene Discovery Technologies Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Avipep Pty Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bayer AG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by BeiGene Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bio-Path Holdings Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Co, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Carrick Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Catalent Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectar Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellestia Biotech AG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celularity Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkmate Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkpoint Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Chimeric Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CSL Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CStone Pharmaceuticals Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Daiichi Sankyo Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Dyadic International Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Eutilex Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Faron Pharmaceuticals Oy, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Genentech USA Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gibson Oncology LLC, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gilead Sciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Glenmark Pharmaceuticals Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hangzhou Sumgen Biotech Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Helocyte Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by HRAIN Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hutchison MediPharma Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Immune Cell Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incyte Corp, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Inhibrx Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Innovent Biologics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Intellia Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kymera Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by LegoChem Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Luye Pharma Group Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Magenta Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Marker Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by MediSix Therapeutics Pte Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck & Co Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck KGaA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Millennium Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Miltenyi Biotec BV & Co KG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Mirati Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NewBio Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Northlake International LLC, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by OncoTartis Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Ono Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Pfizer Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by PlantForm Corp, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Protheragen Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rafael Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by RAPT Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rhizen Pharmaceuticals SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rich Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sanofi, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Seagen Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai First Song Therapeutics Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shattuck Labs Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by SpecificiT Pharma Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Suzhou Everhealth Biomedical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Syndax Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tacitus Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tessa Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tevogen Bio Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tubulis GmbH, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tyme Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Vincerx Pharma Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Viracta Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Waterstone Hanxbio Pty Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Xencor Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the B-Cell Hodgkin Lymphoma Pipeline market?

    In the B-Cell Hodgkin Lymphoma Pipeline market, the key targets are Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2 and Cells Expressing B Lymphocyte Antigen CD19.

  • What are the types of MoA in the B-Cell Hodgkin Lymphoma Pipeline market?

    The key mechanisms of action in the B-Cell Hodgkin Lymphoma Pipeline market are Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor.

  • What are the types of RoA in the B-Cell Hodgkin Lymphoma Pipeline market?

    The types of key RoA in the B-Cell Hodgkin Lymphoma Pipeline market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, Intralesional, Intraperitoneal, and Topical.

  • What are the key molecule types in the B-Cell Hodgkin Lymphoma Pipeline market?

    In the B-Cell Hodgkin Lymphoma Pipeline market, the key molecule types are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, cell therapy, fusion protein, antibody, antisense RNAi oligonucleotide, gene therapy, and oligonucleotide.

  • What are the key companies in the B-Cell Hodgkin Lymphoma Pipeline market?

    The key companies in the B-Cell Hodgkin Lymphoma Pipeline market are Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.